By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited (TEVJF)

OTC Currency in USD
$14.32
$0.00
0.00%
Last Update: 2 Sept 2025, 00:00
$16.42B
Market Cap
-89.50
P/E Ratio (TTM)
Forward Dividend Yield
$13.73 - $22.91
52 Week Range

TEVJF Stock Price Chart

Explore Teva Pharmaceutical Industries Limited interactive price chart. Choose custom timeframes to analyze TEVJF price movements and trends.

TEVJF Company Profile

Discover essential business fundamentals and corporate details for Teva Pharmaceutical Industries Limited (TEVJF) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

18 Jun 2010

Employees

37.00K

CEO

Richard D. Francis

Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

TEVJF Financial Timeline

Browse a chronological timeline of Teva Pharmaceutical Industries Limited corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 12 May 2026

Upcoming earnings on 27 Jan 2026

Upcoming earnings on 4 Nov 2025

Earnings released on 30 Jul 2025

EPS came in at $0.24 falling short of the estimated $0.62 by -60.63%, while revenue for the quarter reached $4.18B , missing expectations by -4.32%.

Earnings released on 7 May 2025

EPS came in at $0.18 falling short of the estimated $0.46 by -59.51%, while revenue for the quarter reached $3.89B , missing expectations by -11.19%.

Earnings released on 29 Jan 2025

EPS came in at -$0.19 falling short of the estimated $0.70 by -127.49%, while revenue for the quarter reached $4.23B , beating expectations by +3.34%.

Earnings released on 6 Nov 2024

EPS came in at -$0.39 falling short of the estimated $0.66 by -158.09%, while revenue for the quarter reached $4.33B , beating expectations by +4.08%.

Earnings released on 31 Jul 2024

EPS came in at -$0.74 falling short of the estimated $0.54 by -237.45%, while revenue for the quarter reached $4.10B , beating expectations by +4.47%.

Earnings released on 8 May 2024

EPS came in at -$0.12 falling short of the estimated $0.52 by -123.55%, while revenue for the quarter reached $3.80B , beating expectations by +0.24%.

Earnings released on 31 Jan 2024

EPS came in at $0.38 falling short of the estimated $0.79 by -52.06%, while revenue for the quarter reached $4.46B , beating expectations by +7.82%.

Earnings released on 9 Nov 2023

EPS came in at $0.07 falling short of the estimated $0.62 by -88.71%, while revenue for the quarter reached $3.85B , beating expectations by +0.60%.

Earnings released on 2 Aug 2023

EPS came in at -$0.77 falling short of the estimated $0.52 by -247.90%, while revenue for the quarter reached $3.88B , beating expectations by +5.30%.

Earnings released on 10 May 2023

EPS came in at -$0.21 falling short of the estimated $0.56 by -138.62%, while revenue for the quarter reached $3.66B , beating expectations by +1.75%.

Earnings released on 8 Feb 2023

EPS came in at $0.71 falling short of the estimated $0.76 by -6.58%, while revenue for the quarter reached $3.88B , beating expectations by +0.82%.

Earnings released on 3 Nov 2022

EPS came in at $0.59 falling short of the estimated $0.63 by -6.35%, while revenue for the quarter reached $3.60B , missing expectations by -3.70%.

Earnings released on 26 Jul 2022

EPS came in at $0.68 surpassing the estimated $0.60 by +13.33%, while revenue for the quarter reached $3.79B , beating expectations by +2.67%.

Earnings released on 3 May 2022

EPS came in at $0.55 falling short of the estimated $0.61 by -9.84%, while revenue for the quarter reached $3.66B , missing expectations by -3.05%.

Earnings released on 9 Feb 2022

EPS came in at $0.77 surpassing the estimated $0.72 by +6.94%, while revenue for the quarter reached $4.10B , missing expectations by -6.43%.

Earnings released on 27 Oct 2021

EPS came in at $0.59 falling short of the estimated $0.64 by -7.81%, while revenue for the quarter reached $3.89B , missing expectations by -7.25%.

Earnings released on 28 Jul 2021

EPS came in at $0.59 falling short of the estimated $0.63 by -6.35%, while revenue for the quarter reached $3.91B .

Earnings released on 28 Apr 2021

EPS came in at $0.63 surpassing the estimated $0.61 by +3.28%, while revenue for the quarter reached $3.98B , beating expectations by +3.39%.

Earnings released on 10 Feb 2021

EPS came in at $0.68 surpassing the estimated $0.63 by +7.94%, while revenue for the quarter reached $4.45B , missing expectations by -70.97%.

Earnings released on 5 Nov 2020

EPS came in at $0.58 falling short of the estimated $0.59 by -1.69%, while revenue for the quarter reached $3.98B .

TEVJF Stock Performance

Access detailed TEVJF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run